The Ser96Ala variant in histidine-rich calcium-binding protein is associated with life-threatening ventricular arrhythmias in idiopathic dilated cardiomyopathy

Demetrios A Arvanitis, Despina Sanoudou, Fotis Kolokathis, Elizabeth Vafiadaki, Vasiliki Papalouka, Aikaterini Kontrogianni-Konstantopoulos, George N Theodorakis, Ioannis A Paraskevaidis, Stamatios Adamopoulos, Gerald W Dorn 2nd, Dimitrios Th Kremastinos, Evangelia G Kranias, Demetrios A Arvanitis, Despina Sanoudou, Fotis Kolokathis, Elizabeth Vafiadaki, Vasiliki Papalouka, Aikaterini Kontrogianni-Konstantopoulos, George N Theodorakis, Ioannis A Paraskevaidis, Stamatios Adamopoulos, Gerald W Dorn 2nd, Dimitrios Th Kremastinos, Evangelia G Kranias

Abstract

Aims: To investigate whether genetic variants of the histidine-rich calcium (HRC)-binding protein are associated with idiopathic dilated cardiomyopathy (DCM) and its progression.

Methods and results: We screened 123 idiopathic DCM patients and 96 healthy individuals by single-strand conformation polymorphism analysis and direct sequencing for genetic variants in HRC. Six polymorphisms were detected: Leu35Leu (A/G), Ser43Asn (G/A), Ser96Ala (T/G), Glu202_Glu203insGlu (-/GAG), Asp261del (GAT/-), and an in-frame insertion of 51 amino acids at His321. The analysis of their frequencies did not reveal any significant correlation with DCM development. However, the Ser96Ala polymorphism exhibited a statistically significant correlation with the occurrence of life-threatening ventricular arrhythmias. During a follow-up of 4.02 +/- 2.4 years, the risk for ventricular arrhythmias was higher (HR, 9.620; 95% CI, 2.183-42.394; P = 0.003) in the Ala/Ala patients, compared with Ser/Ser homozygous patients. On multivariable Cox regression analysis, the Ser96Ala polymorphism was the only significant genetic arrythmogenesis predictor in DCM patients (HR, 4.191; 95% CI, 0.838-20.967; P = 0.018).

Conclusion: The Ser96Ala genetic variant of HRC is associated with life-threatening ventricular arrhythmias in idiopathic DCM and may serve as an independent predictor of susceptibility to arrhythmogenesis in the setting of DCM.

Figures

Figure 1
Figure 1
Intracardiac electrograms showing recording of monomorphic (A) or polymorphic (B) ventricular tachycardia that terminated after implantable cardioverter-defibrillator firing, from two patients with Ala/Ala at codon 96. Their resting ECGs are also presented (C and D, respectively).
Figure 2
Figure 2
Representative example of single strand conformational polymorphism analysis of HRC exon 1 with primer set 7, where the insertion of 51 amino acid residues was found. (A) Single strand conformational polymorphism analysis on 0.5× MDE polyacrylamide gels of three wild types (lanes 1–3), and one heterozygote for the insertion (lane 4). (B) Same set of DNA products (lanes 1–4) analysed in a 2% agarose gel, stained with ethidium bromide; M, 100 bp ladder; second to fourth lanes, wild-type samples; fifth lane, heterozygote for the insertion. (C) DNA sequences: top line, amino acid residues; bottom line, nucleotide sequence. (D) Alignment of the 10 histidine-rich and acidic tandem repeats of the wild-type histidine-rich calcium. The dashed lines indicate gaps for the best fit of the alignment. (E) Alignment of the histidine-rich and acidic tandem repeats of the mutant histidine-rich calcium with the 51 amino acids insertion (in bold, highlighted). The dashed lines indicate gaps for the best fit of the alignment. The in-frame insertion at position 321 adds two extra repeats to the protein.
Figure 3
Figure 3
Group analysis of the relative risk of dilated cardiomyopathy development associated with each of the histidine-rich calcium genotypes detected in dilated cardiomyopathy patients and healthy controls. The number of dilated cardiomyopathy cases and controls with a specific genotype are presented. Each genotype was compared with the rest, as indicated. None of the differences between polymorphism frequencies was statistically significant.
Figure 4
Figure 4
The histidine-rich calcium polymorphism at position 96 is associated with the history of sustained ventricular tachycardia or ventricular fibrillation of dilated cardiomyopathy patients prior to study entry. Percentages of dilated cardiomyopathy patients with Ser/Ser, Ser/Ala, and Ala/Ala at codon 96 in need of implantable cardioverter-defibrillator implantation during study entry (*, χ2 = 11.710, df = 2, P = 0.003).
Figure 5
Figure 5
Relative risk of dilated cardiomyopathy patients for implantable cardioverter-defibrillator implantation (history of sustained ventricular tachycardia or ventricular fibrillation prior to study entry) with respect to histidine-rich calcium polymorphisms. The numbers of dilated cardiomyopathy patients with and without an implantable cardioverter-defibrillator, respectively, with a specific genotype are presented. Each genotype was compared with the rest as indicated. Asterisks indicate statistically significant difference. Homozygosity for alanine of the histidine-rich calcium Ser96Ala polymorphism was associated with an increased risk for malignant ventricular arrhythmias in dilated cardiomyopathy patients prior to study entry, while homozygosity for serine was protective.
Figure 6
Figure 6
Kaplan–Meier plots for the probability of survival from: (A) life-threatening ventricular arrhythmic events including sudden cardiac death and episodes of unstable VT (>180 b.p.m.) or ventricular fibrillation, which were recorded by an implantable cardioverter-defibrillator device and (B) cardiac death from any cause, including pump failure, transplantation, sudden cardiac death, and episodes of unstable VT (>180 b.p.m.) or ventricular fibrillation, which were recorded by an implantable cardioverter-defibrillator device. Each event is depicted as a step down. Each censored case [due to (A) death from other causes except sudden cardiac death, heart transplantation, and study termination and (B) death from non-cardiac aetiology and study termination] is marked with a cross. The table at the bottom of the plots indicates the number of dilated cardiomyopathy patients in risk for each year of the follow-up study. The Ala/Ala homozygotes for the Ser96Ala polymorphism were statistically more susceptible to ventricular arrhythmic events, compared with Ser/Ala heterozygotes and Ser/Ser homozygotes.

References

    1. Zipes DP, Wellens HJ. Sudden cardiac death. Circulation. 1998;98:2334–2351.
    1. Grimm W, Maisch B. Sudden cardiac death in dilated cardiomyopathy—therapeutic options. Herz. 2002;27:750–759.
    1. Hasenfuss G. Alterations of calcium-regulatory proteins in heart failure. Cardiovasc Res. 1998;37:279–289.
    1. Haghighi K, Schmidt AG, Hoit BD, Brittsan AG, Yatani A, Lester JW, Zhai J, Kimura Y, Dorn GW, II, MacLennan DH, Kranias EG. Superinhibition of sarcoplasmic reticulum function by phospholamban induces cardiac contractile failure. J Biol Chem. 2001;276:24145–24152.
    1. Schmidt AG, Zhai J, Carr AN, Gerst MJ, Lorenz JN, Pollesello P, Annila A, Hoit BD, Kranias EG. Structural and functional implications of the phospholamban hinge domain: impaired SR Ca2+ uptake as a primary cause of heart failure. Cardiovasc Res. 2002;56:248–259.
    1. Pogwizd SM, Bers DM. Cellular basis of triggered arrhythmias in heart failure. Trends Cardiovasc Med. 2004;14:61–66.
    1. Janse MJ. Electrophysiological changes in heart failure and their relationship to arrhythmogenesis. Cardiovasc Res. 2004;61:208–217.
    1. Lee HG, Kang H, Kim DH, Park WJ. Interaction of HRC (histidine-rich Ca(2+)-binding protein) and triadin in the lumen of sarcoplasmic reticulum. J Biol Chem. 2001;276:39533–39538.
    1. Kim E, Shin DW, Hong CS, Jeong D, Kim do H, Park WJ. Increased Ca2+ storage capacity in the sarcoplasmic reticulum by overexpression of HRC (histidine-rich Ca2+ binding protein) Biochem Biophys Res Commun. 2003;300:192–196.
    1. Fan GC, Gregory KN, Zhao W, Park WJ, Kranias EG. Regulation of myocardial function by histidine-rich, calcium-binding protein. Am J Physiol Heart Circ Physiol. 2004;287:H1705–H1711.
    1. Gregory KN, Ginsburg KS, Bodi I, Hahn H, Marreez YM, Song Q, Padmanabhan PA, Mitton BA, Waggoner JR, Del Monte F, Park WJ, Ii GW, Bers DM, Kranias EG. Histidine-rich Ca binding protein: a regulator of sarcoplasmic reticulum calcium sequestration and cardiac function. J Mol Cell Cardiol. 2006;40:653–665.
    1. Richardson P, McKenna W, Bristow M, Maisch B, Mautner B, O’Connell J, Olsen E, Thiene G, Goodwin J, Gyarfas I, Martin I, Nordet P. Report of the 1995 World Health Organization/International Society and Federation of Cardiology Task Force on the definition and classification of cardiomyopathies. Circulation. 1996;93:841–842.
    1. Guo SW, Thompson EA. Performing the exact test of Hardy–Weinberg proportion for multiple alleles. Biometrics. 1992;48:361–372.
    1. Lewis CM. Genetic association studies: design, analysis and interpretation. Brief Bioinform. 2002;3:146–153.
    1. Al-Khatib SM, Sanders GD, Bigger JT, Buxton AE, Califf RM, Carlson M, Curtis A, Curtis J, Fain E, Gersh BJ, Gold MR, Haghighi-Mood A, Hammill SC, Healey J, Hlatky M, Hohnloser S, Kim RJ, Lee K, Mark D, Mianulli M, Mitchell B, Prystowsky EN, Smith J, Steinhaus D, Zareba W. Preventing tomorrow’s sudden cardiac death today: part I: current data on risk stratification for sudden cardiac death. Am Heart J. 2007;153:941–950.
    1. Grimm W, Christ M, Bach J, Muller HH, Maisch B. Noninvasive arrhythmia risk stratification in idiopathic dilated cardiomyopathy: results of the Marburg Cardiomyopathy Study. Circulation. 2003;108:2883–2891.
    1. Bansch D, Antz M, Boczor S, Volkmer M, Tebbenjohanns J, Seidl K, Block M, Gietzen F, Berger J, Kuck KH. Primary prevention of sudden cardiac death in idiopathic dilated cardiomyopathy: the Cardiomyopathy Trial (CAT) Circulation. 2002;105:1453–1458.
    1. Bardy GH, Lee KL, Mark DB, Poole JE, Packer DL, Boineau R, Domanski M, Troutman C, Anderson J, Johnson G, McNulty SE, Clapp-Channing N, Davidson-Ray LD, Fraulo ES, Fishbein DP, Luceri RM, Ip JH. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med. 2005;352:225–237.
    1. Priori SG, Napolitano C, Tiso N, Memmi M, Vignati G, Bloise R, Sorrentino V, Danieli GA. Mutations in the cardiac ryanodine receptor gene (hRyR2) underlie catecholaminergic polymorphic ventricular tachycardia. Circulation. 2001;103:196–200.
    1. Laitinen PJ, Brown KM, Piippo K, Swan H, Devaney JM, Brahmbhatt B, Donarum EA, Marino M, Tiso N, Viitasalo M, Toivonen L, Stephan DA, Kontula K. Mutations of the cardiac ryanodine receptor (RyR2) gene in familial polymorphic ventricular tachycardia. Circulation. 2001;103:485–490.
    1. Tiso N, Stephan DA, Nava A, Bagattin A, Devaney JM, Stanchi F, Larderet G, Brahmbhatt B, Brown K, Bauce B, Muriago M, Basso C, Thiene G, Danieli GA, Rampazzo A. Identification of mutations in the cardiac ryanodine receptor gene in families affected with arrhythmogenic right ventricular cardiomyopathy type 2 (ARVD2) Hum Mol Genet. 2001;10:189–194.
    1. Eldar M, Pras E, Lahat H. A missense mutation in the CASQ2 gene is associated with autosomal-recessive catecholamine-induced polymorphic ventricular tachycardia. Trends Cardiovasc Med. 2003;13:148–151.
    1. Haga H, Yamada R, Ohnishi Y, Nakamura Y, Tanaka T. Gene-based SNP discovery as part of the Japanese Millennium Genome Project: identification of 190,562 genetic variations in the human genome. Single-nucleotide polymorphism. J Hum Genet. 2002;47:605–610.
    1. Hofmann SL, Topham M, Hsieh CL, Francke U. cDNA and genomic cloning of HRC, a human sarcoplasmic reticulum protein, and localization of the gene to human chromosome 19 and mouse chromosome 7. Genomics. 1991;9:656–669.
    1. Blom N, Gammeltoft S, Brunak S. Sequence and structure-based prediction of eukaryotic protein phosphorylation sites. J Mol Biol. 1999;294:1351–1362.
    1. Blom N, Sicheritz-Ponten T, Gupta R, Gammeltoft S, Brunak S. Prediction of post-translational glycosylation and phosphorylation of proteins from the amino acid sequence. Proteomics. 2004;4:1633–1649.
    1. Shoshan-Barmatz V, Orr I, Weil S, Meyer H, Varsanyi M, Heilmeyer LM. The identification of the phosphorylated 150/160-kDa proteins of sarcoplasmic reticulum, their kinase and their association with the ryanodine receptor. Biochim Biophys Acta. 1996;1283:89–100.
    1. Hadad N, Meyer HE, Varsanyi M, Fleischer S, Shoshan-Barmatz V. Cardiac sarcalumenin: phosphorylation, comparison with the skeletal muscle sarcalumenin and modulation of ryanodine receptor. J Membr Biol. 1999;170:39–49.
    1. Cala SE, Jones LR. Phosphorylation of cardiac and skeletal muscle calsequestrin isoforms by casein kinase II. Demonstration of a cluster of unique rapidly phosphorylated sites in cardiac calsequestrin. J Biol Chem. 1991;266:391–398.
    1. Szegedi C, Sarkozi S, Herzog A, Jona I, Varsanyi M. Calsequestrin: more than ‘only’ a luminal Ca2+ buffer inside the sarcoplasmic reticulum. Biochem J. 1999;337:19–22.
    1. Arvanitis DA, Vafiadaki E, Fan GC, Mitton BA, Gregory KN, Del Monte F, Kontrogianni-Konstantopoulos A, Sanoudou D, Kranias EG. Histidine-rich Ca-binding protein interacts with sarcoplasmic reticulum Ca-ATPase. Am J Physiol Heart Circ Physiol. 2007;293:H1581–H1589.
    1. Rosen MR, Fisch C, Hoffman BF, Danilo P, Jr, Lovelace DE, Knoebel SB. Can accelerated atrioventricular junctional escape rhythms be explained by delayed afterdepolarizations? Am J Cardiol. 1980;45:1272–1284.
    1. Nataraj AJ, Olivos-Glander I, Kusukawa N, Highsmith WE., Jr Single-strand conformation polymorphism and heteroduplex analysis for gel-based mutation detection. Electrophoresis. 1999;20:1177–1185.

Source: PubMed

스폰서 및 공동 작업자

건강 상태

약물 개입

3
구독하다